Illumina Inc (ILMN) has been making strides in the bio-tech market with a series of significant updates. Several investment firms, including
Douglas Lane & Associates LLC, have increased their stock positions. The company is expected to announce its
Q4 and full year 2024 financial results on February 6, 2025. Illumina is expanding its
TruSight Oncology portfolio and launching a more affordable
NovaSeq X System. The company's stocks are targeted by
activist hedge funds due to their long-term momentum. Illumina is expected to showcase steady growth in their upcoming earnings report with Leerink Partners issuing a positive
Q1 earnings forecast. A recent acquisition of
Fluent BioSciences aims to broaden single-cell analysis. The spin-off of
GRAIL has also been approved by the board of directors. Despite a decrease in price target from Evercore ISI, Illumina's financial performance, growing precision in genetic testing, and advancements in genomic technology position the company as a strong contender in the market.
Illumina ILMN News Analytics from Wed, 29 May 2024 07:00:00 GMT to Fri, 10 Jan 2025 04:05:24 GMT -
Rating 5
- Innovation 7
- Information 6
- Rumor -4
